Prognostic value of CD4+ T lymphopenia in non-small cell lung Cancer - Archive ouverte HAL Access content directly
Journal Articles BMC Cancer Year : 2022

Prognostic value of CD4+ T lymphopenia in non-small cell lung Cancer

(1, 2, 3) , (1, 2, 3) , (2, 3, 4) , (1) , (1) , (1) , (1) , (1) , (1) , (1) , (5) , (5) , (2, 3, 4, 1) , (2, 3, 1)
1
2
3
4
5

Abstract

Background: There is a paucity of data regarding the prognostic influence of peripheral blood CD4+ T lymphopenia in non-small cell lung cancer (NSCLC). Therefore, we investigated the prognostic value of T lymphopenia in NSCLC. Materials: Treatment-naive patients with a pathological diagnosis of NSCLC, at clinical stage I to IV were included in the prospective TELOCAP1 study. Lymphocytes count was evaluated in peripheral blood by flow cytometry. CD4+ and CD8+ T lymphopenia were defined as an absolute count of < 500/μL and < 224/μL respectively. The prognostic value of T lymphopenia was analyzed in the whole population, in local/loco-regional (stage I-IIIB) and in advanced (stage IV) NSCLC disease, using the Kaplan-Meier method and Cox regression models for survival curves and multivariate analysis, respectively. Results: Between July 2010 and January 2014, 169 evaluable patients with clinical stage I to IV NSCLC were prospectively enrolled. The prevalence of CD4+ and CD8+ T lymphopenia was similar in the study population (around 29%). Patients with CD4+ T lymphopenia showed lower overall survival than those with CD4+ T lymphocytes count > 500/ μL (median overall survival (OS) 16.1 versus 21.7 months, hazard ratio (HR): 1.616 [95% CI: 1.1-2.36], p = 0.012). This association with OS was especially marked in local/loco-regional NSCLC stages (median OS, 21.8 versus 72 months, respectively, HR: 1.88 [95% CI: 0.9-3.8], p = 0.035). Multivariate analysis confirmed the worse prognosis associated with CD4+ T lymphopenia in local/loco-regional NSCLC, but not in metastatic patients (HR 2.028 [95% CI = 1.065-3.817] p = 0.02). Restricted cubic spline analysis showed that patients with CD4+ T lymphocytes count ≤500/μL displayed a high risk of death regardless of NSCLC clinical stage. There was no obvious relationship between CD8+ T lymphopenia and clinical outcome. Conclusion: We identified CD4+ T lymphopenia as an independent prognostic factor in local/loco-regional stages of NSCLC and CD4+ T lymphopenia is also associated with a high risk of death, regardless of NSCLC clinical stage.
Fichier principal
Vignette du fichier
s12885-022-09628-8.pdf (1.66 Mo) Télécharger le fichier
Origin : Publisher files allowed on an open archive

Dates and versions

inserm-03690890 , version 1 (08-06-2022)

Identifiers

Cite

Guillaume Eberst, Dewi Vernerey, Caroline Laheurte, Aurélia Meurisse, Vincent Kaulek, et al.. Prognostic value of CD4+ T lymphopenia in non-small cell lung Cancer. BMC Cancer, 2022, 22 (1), pp.529. ⟨10.1186/s12885-022-09628-8⟩. ⟨inserm-03690890⟩

Collections

INSERM UNIV-FCOMTE
0 View
4 Download

Altmetric

Share

Gmail Facebook Twitter LinkedIn More